After the U.S. Court of Appeals for the Federal Circuit rejected Regeneron’s (REGN) request to temporarily block the launch during its appeal of a related decision for Amgen (AMGN) in a patent case in West Virginia, an Amgen spokesperson said the company will launch its biosimilar version of Regeneron’s blockbuster eye care drug Eylea, Reuters reported.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMGN:
- Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo
- RBC would buy Regeneron on weakness with biosimilar Eylea priced in
- Morgan Stanley names Amgen ‘catalyst-driven idea’ into Phase 2 MariTide data
- Amgen price target raised to $383 from $381 at TD Cowen
- Uber downgraded, Zoom Video upgraded: Wall Street’s top analyst calls
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
